XOPENEX Drug Patent Profile
✉ Email this page to a colleague
When do Xopenex patents expire, and what generic alternatives are available?
Xopenex is a drug marketed by Hikma and Lupin and is included in two NDAs. There is one patent protecting this drug and two Paragraph IV challenges.
The generic ingredient in XOPENEX is levalbuterol tartrate. There are nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the levalbuterol tartrate profile page.
DrugPatentWatch® Generic Entry Outlook for Xopenex
There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for XOPENEX?
- What are the global sales for XOPENEX?
- What is Average Wholesale Price for XOPENEX?
Summary for XOPENEX
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 112 |
Clinical Trials: | 6 |
Patent Applications: | 5,154 |
Drug Prices: | Drug price information for XOPENEX |
Drug Sales Revenues: | Drug sales revenues for XOPENEX |
What excipients (inactive ingredients) are in XOPENEX? | XOPENEX excipients list |
DailyMed Link: | XOPENEX at DailyMed |
![XOPENEX drug patent expirations Drug patent expirations by year for XOPENEX](/p/graph/s/t/XOPENEX-patent-expirations.png)
![Drug Prices for XOPENEX](/p/graph/drug-price/XOPENEX.png)
![Drug Sales Revenue Trends for XOPENEX](/p/graph/drug-sales-revenues/XOPENEX.png)
Recent Clinical Trials for XOPENEX
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Henry Ford Health System | Phase 4 |
Genesys Regional Medical Center | Phase 4 |
Ascension Genesys Hospital | Phase 4 |
Paragraph IV (Patent) Challenges for XOPENEX
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
XOPENEX | Inhalation Solution | levalbuterol hydrochloride | 0.25% | 020837 | 1 | 2006-05-23 |
XOPENEX | Inhalation Solution | levalbuterol hydrochloride | 0.0103%, 0.021% and 0.042% | 020837 | 1 | 2005-06-20 |
US Patents and Regulatory Information for XOPENEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hikma | XOPENEX | levalbuterol hydrochloride | SOLUTION;INHALATION | 020837-003 | Jan 30, 2002 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hikma | XOPENEX | levalbuterol hydrochloride | SOLUTION;INHALATION | 020837-004 | Jul 18, 2003 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Hikma | XOPENEX | levalbuterol hydrochloride | SOLUTION;INHALATION | 020837-001 | Mar 25, 1999 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for XOPENEX
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Hikma | XOPENEX | levalbuterol hydrochloride | SOLUTION;INHALATION | 020837-001 | Mar 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
Hikma | XOPENEX | levalbuterol hydrochloride | SOLUTION;INHALATION | 020837-003 | Jan 30, 2002 | ⤷ Sign Up | ⤷ Sign Up |
Hikma | XOPENEX | levalbuterol hydrochloride | SOLUTION;INHALATION | 020837-001 | Mar 25, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for XOPENEX
See the table below for patents covering XOPENEX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Germany | 69209490 | ⤷ Sign Up | |
Japan | 3085705 | ⤷ Sign Up | |
Finland | 932540 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |